Tricida Inc (NASDAQ:TCDA) Director Klaus R. Dr Veitinger sold 3,492 shares of Tricida stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $36.30, for a total transaction of $126,759.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
NASDAQ TCDA opened at $33.23 on Friday. The company has a quick ratio of 8.30, a current ratio of 8.30 and a debt-to-equity ratio of 0.24. Tricida Inc has a 12-month low of $19.43 and a 12-month high of $42.80. The firm has a market capitalization of $1.66 billion and a P/E ratio of -7.16. The firm has a 50 day simple moving average of $36.29.
Tricida (NASDAQ:TCDA) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.10). On average, sell-side analysts predict that Tricida Inc will post -3.44 earnings per share for the current fiscal year.
A number of brokerages have weighed in on TCDA. Cowen reaffirmed a “buy” rating and issued a $50.00 price target on shares of Tricida in a research note on Tuesday, June 25th. Goldman Sachs Group assumed coverage on shares of Tricida in a research note on Wednesday, June 26th. They issued a “buy” rating and a $48.00 price target on the stock. Zacks Investment Research downgraded shares of Hollysys Automation Technologies from a “hold” rating to a “sell” rating in a report on Thursday, April 11th. Empire lifted their price objective on shares of Tricida from $37.00 to $58.00 in a report on Monday, April 1st. Finally, Needham & Company LLC lifted their price objective on shares of ViaSat from $78.00 to $100.00 and gave the company a “buy” rating in a report on Friday, May 24th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Tricida currently has an average rating of “Buy” and an average price target of $47.00.
Several hedge funds and other institutional investors have recently bought and sold shares of TCDA. Quantamental Technologies LLC acquired a new position in Tricida during the first quarter worth $39,000. Marshall Wace North America L.P. increased its holdings in Tricida by 99.0% during the first quarter. Marshall Wace North America L.P. now owns 2,591 shares of the company’s stock worth $100,000 after buying an additional 1,289 shares during the last quarter. Great West Life Assurance Co. Can acquired a new position in Tricida during the fourth quarter worth $71,000. SG Americas Securities LLC acquired a new position in Tricida during the first quarter worth $143,000. Finally, BNP Paribas Arbitrage SA increased its holdings in Tricida by 1,586.2% during the first quarter. BNP Paribas Arbitrage SA now owns 4,030 shares of the company’s stock worth $156,000 after buying an additional 3,791 shares during the last quarter. Institutional investors own 62.89% of the company’s stock.
Tricida Company Profile
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
Recommended Story: How does new data get added to a blockchain?
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.